检索结果-南通市图书馆

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

印度印刷出版业的主要信息资源

印刷世界 2009年第8期14卷 60-61页

作者：王以俊 manish Ranjan Haresh kumar

出版和印刷业在印度已发展到了一个高度竞争的阶段。相中一个故事并出版它需要耗费大量的精力。一本失败的书可能白费了出版商的金钱，反之一本成功的书就意味着升上顶端，因此出版商现在面临着许多的竞争。此外这个行业的主要成员印刷... 详细信息

出版和印刷业在印度已发展到了一个高度竞争的阶段。相中一个故事并出版它需要耗费大量的精力。一本失败的书可能白费了出版商的金钱，反之一本成功的书就意味着升上顶端，因此出版商现在面临着许多的竞争。此外这个行业的主要成员印刷商、装订商和纸张供应商，他们构成了印刷和出版业不可或缺的部份。随着时间的推移和技术的进步，出版和印刷已经变成了高消费的行业。

关键词：印刷出版业信息资源印度印刷业供应商竞争行业消费

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Hepatology 2013年第7期5卷 364-371页

作者： Adnan Muhammad manish Dhamija Gitanjali Vidyarthi Donald Amodeo William Boyd Branko Miladinovic Ambuj kumar Department of Gastroenterology University of South Florida Department of Gastroenterology James A Haley VA Hospital Department of Internal Medicine Morsani College of Medicine Center for Evidence Based Medicine

AIM: To compare the overall survival (OS) and progression-free survival (PFS) with associated adverse events (AE) in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) + sorafenib vs TACE alone. METHODS: In this retrospective cohort study we collected data on all consecutive patients with a diagnosis of unresectable HCC between 2007 and 2011 who had been treated with TACE + sorafenib or TACE alone. We hypothesized that the combination therapy is superior to TACE alone in improving the survival in these patients. Data extracted included patient's demographics, etiology of liver disease, histology of HCC, stage of liver disease with respect to model of end stage liverdisease score and Child-Turcotte-Pugh (CTP) classification and Barcelona Clinic Liver Cancer (BCLC) staging for HCC. Computed tomography scan findings, alpha fetoprotein levels, number of treatments and related AE were also recorded and analyzed. RESULTS: Of the 43 patients who met inclusion criteria, 13 were treated with TACE + sorafenib and 30 with TACE alone. There was no significant difference in median survival: 20.6 mo (95%CI: 13.4-38.4) for the TACE + sorafenib and 18.3 mo (95%CI: 11.8-32.9) for the TACE alone (P = 0.72). There were also no statistically significant differences between groups in OS (HR = 0.82, 95%CI: 0.38-1.77; P = 0.61), PFS (HR = 0.93, 95%CI: 0.45-1.89; P = 0.83), and treatment-related toxicities (P = 0.554). CTP classification and BCLC staging for HCC were statistically significant (P = 0.001, P = 0.04 respectively) in predicting the survival in patients with HCC. The common AE observed were abdominal pain, nausea, vomiting and mild elevation of liver enzymes. CONCLUSION: Combination therapy with TACE + sorafenib is safe and equally effective as TACE alone in patients with unresectable HCC. CTP classification and BCLC staging were the significant predictors of survival. Future trials with large number of patients are nee

关键词： Hepatocellular carcinoma Transarterial chemoembolization Sorafenib Survival Adverse events

Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Internal Medicine 2012年第2期2卷 67-71页

作者： manish Maladkar Vijay kumar Verma Keshav A. Narsikar Rajan D. Walinjkar W. R. Patil N. J. S. Saggu Suresh P. Kulkarni 8 Shalom Navi Mumbai India Agarwal Hospital Thane (West) India Clinic 411 Jack Chambers Navi Mumbai India Head-Medical & Regulatory Affairs Aristo Pharmaceuticals Pvt Ltd Mumbai India JN-2/47/P2 Navi Mumbai India Shree Polyclinic 114 Nirman Vyapar Kendra Navi Mumbai India Yash Speciality Clinic Nirman Vyapar Kendra Navi Mumbai India

Background: Triple drug therapy comprising angiotensin receptor blocker (ARB), calcium channel blocker (CCB) and hydrochlorothiazide (HCT) effectively controls essential hypertension as evident from the literature. This study was undertaken to assess the efficacy and safety of triple combination compared to the dual drug therapy. Methodologies: A total of 220 male and female patients with essential hypertension were enrolled in the study. The patients were divided into two groups. Group A received a bilayer tablet of FDC of Telmisartan + Amlodipine + HCT and group B received FDC tablet of Telmisartan + HCT. Both the treatments were administered once daily for twelve weeks. The patients were asked to follow-up on week 1, 2, 4, 6, 8 and 10 for periodic efficacy and safety evaluations. Effect on systolic blood pressure (SBP), diastolic blood pressure (DBP) and quality of life (QOL) were recorded during the course of the trial. Results: Blood pressure reduction (BP) to the desired goals was observed with both the treatments. The SBP and DBP reductions were superior in triple combination therapy than double combination. Both treatments improved QOL of patients. Conclusion: Triple drug combination of telmisartan, amlodipine and HCT may serve a potential role in achieving desired BP goals, in patients with essential hypertension, which are otherwise poorly managed by either monotherapy or dual drug therapy.

关键词： Essential Hypertension Telmisartan Amlodipine and HCT

闪光对于减轻静脉置管痛的作用：一项前瞻性随机安慰剂对照研究

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

麻醉与镇痛 2009年第3期5卷 73-75页

作者： Anil Agarwal GhanshvamYadav Devendra Gupta manish Tandon Prabhat kumar Singh Uttam Singh 吴志林(译) Departments of Anaesthesiology Sanjay Gandhi Post Graduate Institute of Medical Sciences Lucknow India Departments of Biostatics Sanjay Gandhi Post Graduate Institute of Medical Sciences Lucknow India 不详

背景尽管静脉置管时的疼痛经常让人备受困扰，但通常都是在没有任何镇痛措施下进行静脉置管的。临床上曾尝试用一些药物和非药物方法来减轻静脉置管的疼痛，但结果各异。本研究拟评价一次闪光对于减轻静脉置管痛的效果。方法90例拟择期... 详细信息

背景尽管静脉置管时的疼痛经常让人备受困扰，但通常都是在没有任何镇痛措施下进行静脉置管的。临床上曾尝试用一些药物和非药物方法来减轻静脉置管的疼痛，但结果各异。本研究拟评价一次闪光对于减轻静脉置管痛的效果。方法90例拟择期行腹腔镜胆囊切除术的ASAⅠ～Ⅱ级的成年患者（15～60岁），随机分为3组，每组30例，组1为对照组；组2为分散注意力组，即在非优势手的手背静脉进行置管前给患者照相而不使用闪光；组3为闪光组，静脉置管前照相并且使用闪光；在照相后立即使用18G的穿刺针进行静脉置管。结果每组均有2例患者首次静脉穿刺失败，在数据分析中即予以剔除，闪光组疼痛的发生率为50％（28例中14例发生），其他2组为100％（28例全部发生），通过视觉模拟评分评估的疼痛严重程度分散注意力组和闪光组显著低于对照组，而闪光组也显著低于分散注意力组。结论静脉置管前使用闪光是一种减轻疼痛的安全而简单有效的方法。

关键词：静脉置管减轻疼痛安慰剂对照闪光随机腹腔镜胆囊切除术非药物方法静脉穿刺失败

Impact of Climate Change on Diseases of Crops and Their Management-A Review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Agricultural Science and Technology(B) 2022年第1期12卷 1-15页

作者： manish kumar Maurya Vikash kumar Yadav Sumant Pratap Singh Rajender Jatoth Hemant kumar Singh Dinesh Singh Department of Plant Pathology Acharya Narendra Deva University of Agriculture and TechnologyKumarganjAyodhya 224229(U.P.)India Department of Plant Molecular Biology and Genetic Engineering Acharya Narendra Deva University of Agriculture and TechnologyKumarganjAyodhya 224229(U.P.)India Division of Plant Pathology ICAR-Indian Agricultural Research InstituteNew Delhi110012 India

Change in global climate is primarily due to rising concentrations of greenhouse gases in the atmosphere that is mostly caused by human *** important factors affecting the occurrence and spread of the plant diseases are temperature,moisture,light,and CO_(2) *** factors cause physiological changes in plants that result in increase in intensity of crop *** change causes a significant impact on germination,reproduction,sporulation and spore dispersal of *** change affects all life stages of the pathogen as well as its host to cause impact on host-pathogen interaction which facilitates the emergence of new races of the pathogen ultimately breakdowns the host *** also affects the microbial community in the soil which is beneficial to the plants in various *** minor diseases become major ones due to alteration in climatic parameters thus posing a threat to the food security.

关键词： Climate change greenhouse gases temperature elevated CO_(2) pathogens sporulation